National Pension Service Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

National Pension Service grew its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 712,056 shares of the company's stock after acquiring an additional 19,961 shares during the period. National Pension Service owned 0.19% of Moderna worth $70,814,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. International Assets Investment Management LLC lifted its position in Moderna by 6,528.9% during the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company's stock valued at $38,552,000 after purchasing an additional 381,808 shares during the period. abrdn plc raised its position in shares of Moderna by 477.5% during the 4th quarter. abrdn plc now owns 483,574 shares of the company's stock valued at $48,091,000 after acquiring an additional 399,843 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Moderna by 19.2% in the 4th quarter. Van ECK Associates Corp now owns 270,774 shares of the company's stock valued at $26,929,000 after purchasing an additional 43,646 shares during the period. Invesco Ltd. boosted its position in shares of Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock worth $322,887,000 after purchasing an additional 517,683 shares during the last quarter. Finally, First Trust Direct Indexing L.P. bought a new stake in Moderna in the fourth quarter valued at about $372,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of Moderna stock traded up $0.80 during trading on Thursday, hitting $122.69. 3,092,427 shares of the stock were exchanged, compared to its average volume of 4,101,900. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The company has a fifty day moving average price of $106.59 and a 200-day moving average price of $95.24. The stock has a market capitalization of $47.02 billion, a price-to-earnings ratio of -7.89 and a beta of 1.57. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $142.79.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts' consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the previous year, the business earned $0.19 earnings per share. The business's revenue was down 91.0% compared to the same quarter last year. As a group, equities analysts predict that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 647 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Moderna news, President Stephen Hoge sold 2,388 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company's stock, valued at approximately $143,358,473.86. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO James M. Mock sold 647 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock valued at $14,822,576 in the last quarter. 15.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MRNA shares. William Blair restated a "market perform" rating on shares of Moderna in a research report on Monday, April 1st. UBS Group upped their target price on shares of Moderna from $143.00 to $151.00 and gave the company a "buy" rating in a research note on Tuesday. HSBC reissued a "reduce" rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Canaccord Genuity Group boosted their price target on shares of Moderna from $91.00 to $106.00 and gave the company a "hold" rating in a report on Friday, May 3rd. Finally, Royal Bank of Canada raised their price objective on Moderna from $125.00 to $135.00 and gave the stock an "outperform" rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $126.89.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.